Press Release Details

Cerus Corporation Appoints Dr. Joseph Eiden Vice President, Clinical Research and Medical Affairs

July, 19 2005

CONCORD, Calif.--(BUSINESS WIRE)--July 19, 2005--Cerus Corporation (NASDAQ:CERS) today announced that Dr. Joseph Eiden has joined the company as vice president, clinical research and medical affairs. Dr. Eiden will oversee the company's clinical development efforts.

Dr. Eiden brings to Cerus an exceptional reputation that is based on more than 20 years of experience. Most recently, Dr. Eiden was senior director of clinical research and medical affairs at Chiron Vaccines, where he guided clinical teams in the United States for development of vaccines for prevention of Neisseria meningitidis, influenza and HIV. Prior to joining Chiron, Dr. Eiden was vice president of medical affairs at Dynavax Technologies Corporation. While at Dynavax, Dr. Eiden also held the position of vice president of research and development.

"We are extremely pleased to have Dr. Eiden join Cerus. His wealth of knowledge and proven abilities in areas of clinical research will truly be a valuable asset to the Company as we move forward in our programs in both blood safety and immunotherapy," said Claes Glassell, president and chief executive officer of Cerus Corporation.

Dr. Eiden received his Ph.D. in Microbiology and Immunology, his M.D. from Duke University and completed his medical training in pediatrics and infectious disease at the Johns Hopkins University School of Medicine, where he also served on the faculty. Additionally, Dr. Eiden has published numerous articles in such publications as Nature, Virology, Biochemistry and Lancet.


Cerus Corporation is developing novel products for cancer, infectious disease and blood safety based on multiple, innovative technology platforms. The company is building a pipeline of next generation cancer immunotherapies by combining its proprietary attenuated Listeria vector platform with promising disease antigens. These products are designed to stimulate innate and T cell immune pathways, generating highly potent anti-tumor responses. Cerus is applying its Helinx technology to develop the INTERCEPT Blood System, which is designed to enhance the safety of blood components through pathogen inactivation. The company's strategy is to leverage the broad potential of its technologies and products through alliances. Cerus' partners to date include MedImmune and Johns Hopkins University for cancer immunotherapy, and Baxter International and BioOne for the INTERCEPT Blood System.

Helinx is a trademark of Cerus Corporation

INTERCEPT is a trademark of Baxter International Inc.

Statements in this news release regarding product development are forward-looking statements that involve risks and uncertainties. Actual results could differ materially from the above forward-looking statements as a result of certain factors, including the risks and uncertainties inherent in developing biotechnology products based on new technologies, actions by collaborators, including the risks and uncertainty of the timing and results of clinical trials and other research and development activities, actions by regulatory authorities at any stage of the development process, additional financing activities, manufacturing, market acceptance of any products, competitive conditions, long-term growth opportunity of Cerus, legal proceedings and other factors discussed in the company's Form 10-Q for the first quarter of fiscal 2005, as well as in other reports filed from time to time with the Securities and Exchange Commission. The company assumes no obligation to update any forward-looking statements.

    CONTACT: Cerus Corporation
             Ruey-Li Hwang, 925-288-6017

    SOURCE: Cerus Corporation

    Global Headquarters

  • 1220 Concord Avenue
  • Concord, CA US 94520
  • +1 925.288.6000

    European Headquarters

  • Stationsstraat 79-D
  • 3811 MH Amersfoort, Netherlands
  • +31 (0) 33 49 60 600